Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors

Isoform-Selective PI3K Inhibitors for Various Diseases

(2020) Rammohan R. Yadav Bheemanaboina   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Discovery of Potent and Selective PI3Kγ Inhibitors

(2020) Samuel L. Drew et al.   JOURNAL OF MEDICINAL CHEMISTRY

Computational investigation of the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib: combined molecular dynamics simulation and free energy calculation

(2020) Jingyu Zhu et al.   STRUCTURAL CHEMISTRY

A class of highly selective inhibitors bind to an active state of PI3Kγ

(2019) Gangadhara Gangadhara et al.   Nature Chemical Biology

Rational Design of Novel Phosphoinositide 3‐kinase Gamma (PI3Kγ) Selective Inhibitors: A Computational Investigation Integrating 3D‐QSAR, Molecular Docking and Molecular Dynamics Simulation

(2019) Kan Li et al.   CHEMISTRY & BIODIVERSITY

Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation

(2019) Jingyu Zhu et al.   JOURNAL OF MOLECULAR MODELING

Continuous Evaluation of Ligand Protein Predictions: A Weekly Community Challenge for Drug Docking

(2019) Jeffrey R. Wagner et al.   STRUCTURE

Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer

(2019) Fatma M. Elmenier et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors

(2018) Nils Pemberton et al.   JOURNAL OF MEDICINAL CHEMISTRY

Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration

(2018) Ahmed Y. Ali et al.   LEUKEMIA

A Phase 1 Study of Alpelisib (BYL719), an α- Specific PI3K Inhibitor, in Japanese Patients with Advanced Solid Tumors

(2018) Yuichi Ando et al.   CANCER SCIENCE

Insight into the selective mechanism of phosphoinositide 3-kinase γ with benzothiazole and thiazolopiperidine γ-specific inhibitors by in silico approaches

(2018) Jingyu Zhu et al.   Chemical Biology & Drug Design

Duvelisib: First Global Approval

(2018) Hannah A. Blair   DRUGS

Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective

(2018) Aimie E. Garces et al.   JOURNAL OF MEDICINAL CHEMISTRY

SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors

(2017) Manman Wei et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer

(2016) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

(2016) Catherine A. Evans et al.   ACS Medicinal Chemistry Letters

Synthesis and SAR study of potent and selective PI3Kδ inhibitors

(2015) Minna Bui et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

PI3K inhibitors in inflammation, autoimmunity and cancer

(2015) Anne-Katrien Stark et al.   CURRENT OPINION IN PHARMACOLOGY

Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies

(2015) Jingyu Zhu et al.   DRUG DISCOVERY TODAY

Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ

(2015) Philip N. Collier et al.   JOURNAL OF MEDICINAL CHEMISTRY

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond

(2015) Manman Wei et al.   MEDICINAL RESEARCH REVIEWS

Molecular Docking and Structure-Based Drug Design Strategies

(2015) Leonardo Ferreira et al.   MOLECULES

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

(2015)   Oncotarget

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

(2015) Jingyu Zhu et al.   Oncotarget

A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo

(2015) Juan Tang et al.   Oncotarget

Structural basis of nSH2 regulation and lipid binding in PI3Kα

(2015) Michelle S. Miller et al.   Oncotarget

Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma

(2014) J. Zhu et al.   CURRENT MEDICINAL CHEMISTRY

Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis

(2014) Mutasem O. Taha et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ

(2014) Philip N. Collier et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers

(2014) Victor Certal et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mechanisms of PI3Kβ-Selective Inhibition Revealed by Reciprocal Mutagenesis

(2013) Zhaohua Zheng et al.   ACS Chemical Biology

Inhibition of phosphoinositide 3-kinase γ attenuates inflammation, obesity, and cardiovascular risk factors

(2013) Matthias P. Wymann et al.   Annals of the New York Academy of Sciences

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

(2013) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

(2013) David G. Winkler et al.   CHEMISTRY & BIOLOGY

Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors

(2013) Jingyu Zhu et al.   Molecular BioSystems

SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors

(2012) Kathryn Bell et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf

(2012) Daniel P. Sutherlin et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease

(2012) Mhairi J. Maxwell et al.   JOURNAL OF AUTOIMMUNITY

Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors

(2012) James W. Leahy et al.   JOURNAL OF MEDICINAL CHEMISTRY

PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases

(2012) Timothy D. Cushing et al.   JOURNAL OF MEDICINAL CHEMISTRY

A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation

(2012) Giovanna Bergamini et al.   Nature Chemical Biology

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799

(2011) Jun Ohwada et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

(2011) Jorge J Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism

(2011) Xuxiao Zhang et al.   MOLECULAR CELL

Isoform-Selective Inhibition of Phosphoinositide 3-Kinase: Identification of a New Region of Nonconserved Amino Acids Critical for p110  Inhibition

(2011) Z. Zheng et al.   MOLECULAR PHARMACOLOGY

Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases

(2011) W-C Hon et al.   ONCOGENE

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Discovery of Dual Inhibitors of the Immune Cell PI3Ks p110δ and p110γ: a Prototype for New Anti-inflammatory Drugs

(2010) Olusegun Williams et al.   CHEMISTRY & BIOLOGY

The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors

(2010) Alex Berndt et al.   Nature Chemical Biology

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

How to obtain statistically converged MM/GBSA results

(2009) Samuel Genheden et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation

(2009) Fabio Zuccotto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket

(2008) Mark Frazzetto et al.   BIOCHEMICAL JOURNAL

Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

(2008) Eli R. Zunder et al.   CANCER CELL